Literature DB >> 29577540

Burden of cardio-renal-metabolic conditions in adults with type 2 diabetes within the Diabetes Collaborative Registry.

Suzanne V Arnold1, Mikhail Kosiborod1, Jingyan Wang1, Peter Fenici2, Goran Gannedahl3, Robert J LoCasale4.   

Abstract

We examined the prevalence of cardio-renal-metabolic (CaReMe) conditions and their combinations among 530 747 adults with type 2 diabetes in a USA-based outpatient registry of 271 primary care, cardiology and endocrinology offices. We evaluated the following CaReMe conditions: hypertension, hyperlipidaemia, coronary artery disease (CAD), chronic kidney disease (CKD), cerebrovascular disease, peripheral artery disease, atrial fibrillation, heart failure, and gout or hyperuricaemia; prevalence estimates were adjusted based on the distribution of diabetes by age in the US population in 2015. We found that it was uncommon for patients to have isolated type 2 diabetes without other CaReMe conditions, with only 6.4% having no other CaReMe conditions and 51% having ≥3 other CaReMe conditions. The most prevalent individual conditions were hypertension (83%), hyperlipidemia (81%), CAD (32%) and CKD (20%), and the most common combinations included various groupings of hypertension, hyperlipidaemia, atherosclerotic cardiovascular disease and CKD. Older age, male sex and tobacco use were each associated with increased numbers of CaReMe conditions. These findings highlight the clinical need for novel treatment strategies for diabetes that address both glycaemia and coexisting disease states.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  cardiometabolic; cardiovascular disease; diabetes mellitus

Mesh:

Year:  2018        PMID: 29577540     DOI: 10.1111/dom.13303

Source DB:  PubMed          Journal:  Diabetes Obes Metab        ISSN: 1462-8902            Impact factor:   6.577


  8 in total

1.  Cost-Effectiveness Analysis of Initiating Type 2 Diabetes Therapy with a Sodium-Glucose Cotransporter 2 Inhibitor Versus Conventional Therapy in Japan.

Authors:  Ataru Igarashi; Keiko Maruyama-Sakurai; Anna Kubota; Hiroki Akiyama; Toshitaka Yajima; Shun Kohsaka; Hiroaki Miyata
Journal:  Diabetes Ther       Date:  2022-06-16       Impact factor: 3.595

2.  Multimorbidity and mortality: A data science perspective.

Authors:  Kien Wei Siah; Chi Heem Wong; Jerry Gupta; Andrew W Lo
Journal:  J Multimorb Comorb       Date:  2022-06-01

3.  Safety and Efficacy of Exenatide Once Weekly in Participants with Type 2 Diabetes and Stage 2/3 Chronic Kidney Disease.

Authors:  Cristian Guja; Juan P Frías; Lisa Suchower; Elise Hardy; Galina Marr; C David Sjöström; Serge A Jabbour
Journal:  Diabetes Ther       Date:  2020-04-18       Impact factor: 2.945

4.  Subclinical atherosclerosis burden predicts cardiovascular events in individuals with diabetes and chronic kidney disease.

Authors:  Ana Palanca; Esmeralda Castelblanco; Àngels Betriu; Hèctor Perpiñán; Berta Soldevila; José Manuel Valdivielso; Marcelino Bermúdez-Lopez; Carlos Puig-Jové; Manel Puig-Domingo; Per-Henrik Groop; Elvira Fernández; Núria Alonso; Didac Mauricio
Journal:  Cardiovasc Diabetol       Date:  2019-07-19       Impact factor: 9.951

Review 5.  Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk.

Authors:  Francesco Giorgino; Jiten Vora; Peter Fenici; Anna Solini
Journal:  Cardiovasc Diabetol       Date:  2020-11-22       Impact factor: 9.951

6.  Use of the ankle-brachial index combined with the percentage of mean arterial pressure at the ankle to improve prediction of all-cause mortality in type 2 diabetes mellitus: an observational study.

Authors:  Yu-Hsuan Li; Wayne Huey-Herng Sheu; I-Te Lee
Journal:  Cardiovasc Diabetol       Date:  2020-10-09       Impact factor: 9.951

Review 7.  Cardiovascular protection with sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: Does it apply to all patients?

Authors:  Francesco Giorgino; Jiten Vora; Peter Fenici; Anna Solini
Journal:  Diabetes Obes Metab       Date:  2020-05-07       Impact factor: 6.577

Review 8.  Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes.

Authors:  Guntram Schernthaner; Naim Shehadeh; Alexander S Ametov; Anna V Bazarova; Fahim Ebrahimi; Peter Fasching; Andrej Janež; Péter Kempler; Ilze Konrāde; Nebojša M Lalić; Boris Mankovsky; Emil Martinka; Dario Rahelić; Cristian Serafinceanu; Jan Škrha; Tsvetalina Tankova; Žydrūnė Visockienė
Journal:  Cardiovasc Diabetol       Date:  2020-10-23       Impact factor: 9.951

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.